In last trading session, Proteostasis Therapeutics, Inc. (NASDAQ:PTI) saw 2,013,741 shares changing hands with its beta currently measuring 1.14. Company’s recent per share price level of $1.17 trading at -$0.02 or -1.68% at ring of the bell on the day assigns it a market valuation of $61.05 Million. That closing price of PTI’s stock is at a discount of -303.42% from its 52-week high price of $4.72 and is indicating a premium of 40.17% from its 52-week low price of $0.7. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 291.31 Million shares which gives us an average trading volume of 837Million if we extend that period to 3-months.

For Proteostasis Therapeutics, Inc. (PTI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.3. Splitting up the data highlights that, out of 3 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 3 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.19 in the current quarter.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) trade information

Wall Street analysts have assigned a consensus price target of $4.67 to the stock, which implies a rise of 299.15% to its current value. Analysts have been projecting $2 as a low price target for the stock while placing it at a high target of $8. It follows that stock’s current price would jump +583.76% in reaching the projected high whereas dropping to the targeted low would mean a loss of 70.94% for stock’s current value.

Proteostasis Therapeutics, Inc. (PTI) estimates and forecasts

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 5.7% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 28% while estimates for its earnings growth in next 5 years are of 0%

Proteostasis Therapeutics, Inc. (NASDAQ:PTI)’s Major holders

Insiders are in possession of 17.86% of company’s total shares while institution are holding 22.55% percent of that, with stock having share float percentage of 27.46%. Investors also watch the number of corporate investors in a company very closely, which is 61 institutions for Proteostasis Therapeutics, Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at PTI for having 1.83 Million shares of worth $2.5 Million. And as of June 29, 2020, it was holding 3.5% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 1.09 Million shares on June 29, 2020. The number of shares represents firm’s hold over 2.08% of outstanding shares, having a total worth of $1.49 Million.

On the other hand, Vanguard Total Stock Market Index Fund and Delaware Group Equity Fds IV-Delaware Healthcare Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 1195732 shares of worth $1.64 Million or 2.29% of the total outstanding shares. The later fund manager was in possession of 750Thousand shares on June 29, 2020, making its stake of worth around $1.03 Million in the company or a holder of 1.44% of company’s stock.